Vol 12, No 1 (2021)
Case report
Published online: 2021-09-29
Ponatinib in treatment of chronic myeloid leukemia with T315I mutation
Hematology in Clinical Practice 2021;12(1):33-35.
Abstract
Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation t(9;22)(q34;q11) which causes the formation of the Philadelphia chromosome (Ph). Therapeutic progress made in the last two decades and new-generation tyrosine kinase inhibitors (TKIs) introduction, signifi cantly increased patients’ prognosis. We present a case study of a Ph-positive CML patient with a point BCR/ABL1 mutation T315I treated with ponatinib.
Keywords: chronic myeloid leukemiaCMLPhiladelphia chromosomeT315I mutationTKIsponatinib
References
- Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. The Lancet. 2007; 370(9584): 342–350.
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
- Harrington P, Kizilors A, de Lavallade H. The role of early molecular response in the management of chronic phase CML. Curr Hematol Malig Rep. 2017; 12(2): 79–84.
- Molica M, Scalzulli E, Colafigli G, et al. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol. 2019; 10: 2040620719826444.
- https://www.ema.europa.eu/en/documents/product.